Molecular mechanisms that desensitize metabotropic glutamate receptor signaling: An overview

The purpose of the present article is to review our actual knowledge on the desensitization of metabotropic glutamate receptors based on the literature available so far, with the attempt to emphasize all converging data and to give a possible explanation to those evidences that still remain controve...

Full description

Saved in:
Bibliographic Details
Published in:Neuropharmacology 2013-03, Vol.66, p.24-30
Main Authors: Iacovelli, Luisa, Nicoletti, Ferdinando, De Blasi, Antonio
Format: Article
Language:English
Subjects:
Animals
Arrestins
Cyclic AMP - antagonists & inhibitors
Cyclic AMP - biosynthesis
Data processing
Extracellular Signal-Regulated MAP Kinases - drug effects
Extracellular Signal-Regulated MAP Kinases - metabolism
GRKs
Humans
Metabotropic glutamate receptors
Receptor desensitization
Receptors, Metabotropic Glutamate - metabolism
Signal Transduction - drug effects
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The purpose of the present article is to review our actual knowledge on the desensitization of metabotropic glutamate receptors based on the literature available so far, with the attempt to emphasize all converging data and to give a possible explanation to those evidences that still remain controversial. 1. We review our knowledge on the regulation of mGlu receptors based on the available literature 2. We report converging data and we comment on issues that still remain controversial. This article is part of a Special Issue entitled ‘Metabotropic Glutamate Receptors’. ► We review our knowledge on the desensitization of mGlu receptors. ► We focus both on converging data and on issues that still remain controversial. ► GRK2 regulates mGlu1 receptor by a phosphorylation-independent mechanism. ► The mGlu2 (but not the mGlu3) receptor is resistant to homologous desensitization.
ISSN:0028-3908
1873-7064
DOI:10.1016/j.neuropharm.2012.05.005